Replies to post #777980 on NorthWest Biotherapeutics Inc (NWBO)

[FeMike]

And while you’re right that “not in a position to submit” could stem from various internal reasons, this is the first time NICE has publicly acknowledged DCVax-L in this context. That alone is new.

Incorrect.

As far back as 2018, NICE confirmed that NWBO was not in a position to submit its evidence package. This is a quote from NICE, this is how you reference actual, real life quotes that you didn't make up:

9 September 2018: The company has informed NICE that, at this time, it cannot provide an evidence submission that is required for this appraisal. Therefore, we are suspending the appraisal while we hold further discussions with the company. We will provide a further update and rescheduled timelines in due course

Are you trying to tell me that DCVax-L was approved in 2018 and we're still just waiting for the PR??